C. R. Bard, Inc. ("Bard") is an American developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties.

According to the Complaint, on April 23, 2017, Bard’s Board of Directors caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with BD. Pursuant to the terms of the Merger Agreement, shareholders of Bard will receive $222.93 in cash and 0.5077 shares of BD stock for each share of Bard common stock.

On May 23, 2017, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

On September 25, 2017, Plaintiff filed a Notice voluntarily dismissing this action.